Navigation Links
ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
Date:1/13/2009

PHILADELPHIA and LYON, France, Jan. 13 /PRNewswire-USNewswire/ -- ERYtech Pharma, French Biotechnology Company, and the Penn Jersey Region of American Red Cross are pleased to announce the signature of an agreement concerning the GMP clinical batches production of ERYtech Pharma's products in the United States.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090113/DC58023LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO)

ERYtech Pharma's co-founder and COO, Pierre-Olivier Goineau says, "this agreement allows ERYtech Pharma to be industrially present in the United States; it is an important step for the development of our products."

"This partnership enables the American Red Cross to show patients and donors that we are committed to providing the best services available," says Brigid O'Neill-LaGier, Chief Executive Officer of the American Red Cross Penn-Jersey Blood Services Region.

ERYtech Pharma's Co-Founder and CEO, Yann Godfrin concludes, "We are pleased to have reached this agreement and we think already to other projects of partnership with the American Red Cross for the development of our products."

About ERYtech Pharma

ERYtech Pharma is a leading biotechnology company developing next generation medicinal products making a huge positive impact on the lives of patients with serious unmet clinical needs.

A pioneer in the encapsulation of therapeutic molecules inside red blood cells, it is developing a pipeline of innovative therapeutics in orphan indications or underserved subpopulation of high risk patient's through its proprietary technology of entrapment and in-depth exploration of red cell physiologic properties.

ERYtech is focused in the fields of Haematology, Oncology and Metabolic Diseases. ERYtech Pharma's most advanced product, GRASPA(R), has completed a Phase II clinical trial in leukaemia and is currently being evaluated in the indication of several solid tumours. Beyond GRASPA(R), ERYtech has several investigational compounds addressing specific unmet clinical needs through enhanced efficacy, better compliance, reduced dosage or increased safety profile.


'/>"/>
SOURCE American Red Cross, Penn-Jersey Region; ERYtech Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
(Date:6/23/2016)... 23, 2016 ReportsnReports.com adds ... to its pharmaceuticals section with historic and forecast ... much more. Complete report on the ... profiling 15 companies and supported with 261 tables ... . The Global Cell Culture ...
(Date:6/22/2016)... -- Research and Markets has announced the addition of ... offering. The global biomarkers ... in 2013. The market is expected to grow at a five-year ... increasing from $50.6 billion in 2015 to $96.6 billion in 2020. ... period (2015 to 2020) are discussed. As well, new products approved ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):